MuScreen™

Screen your compound across well validated panels of Syngeneic and Tumor Homograft models to accelerate your drug development

muscreen-magnify.png

High Throughput In Vivo Screens for Evaluating Immunotherapies

2019 MuScreen Schedules

The MuScreen platform is a high throughput in vivo screen to evaluate immuno- and chemotherapies across a preselected set of well characterized and validated syngeneic or tumor homograft (MuPrime™) models. These screens provide a cost effective and time efficient way to fast-track in vivo preclinical immunotherapy development.

Choose MuScreen to:

  • Benefit from CrownBio covering the cost of the vehicle group for all models

  • Benefit from a discount on shared control groups

  • Quickly identify responder models or markers saving time and improving efficiency

  • Evaluate efficacy and/or pharmacodynamic (PD) effects of your compounds across well characterized syngeneic and tumor homograft models*

*MuScreen-Tumor Homograft currently only available as Efficacy Mode

MuScreen-Syngeneic Model Panel  

MuScreen-Tumor Homograft Model Panel

Efficacy Mode  

PD Mode  

Access the MuBase® Database  



Request MuScreen Pricing